SLIT 预防过敏进程
SLIT's Prevention of the Allergic March.
机构信息
Respiratory Unit, Pediatric Pulmonology & Respiratory Intermediate Care Unit, Sleep and Long Term Ventilation Unit, Academic Department of Pediatrics, Bambino Gesù Children's Hospital, Piazza S. Onofrio 4, 00165, Rome, Italy.
Neonatal Intensive Care Unit, A.O.U.P. "P. Giaccone", Department of Sciences for Health Promotion and Mother and Child Care "G. D'Alessandro", University of Palermo, Via Alfonso Giordano n. 3, 90127, Palermo, Italy.
出版信息
Curr Allergy Asthma Rep. 2018 Apr 21;18(5):31. doi: 10.1007/s11882-018-0785-7.
PURPOSE OF REVIEW
The progression of atopic disorders from atopic dermatitis in infants to allergic rhinitis and asthma in children, adolescents, and adults defines the allergy march. Allergen immunotherapy is the only causal treatment altering the immunological mechanism underlying the allergic diseases. The sublingual administration route is more acceptable than the subcutaneous one in pediatric age.
RECENT FINDINGS
Several studies show the efficacy and safety profile of sublingual immunotherapy (SLIT) for the treatment of respiratory allergy diseases, but few data are available on its effect of primary and secondary prevention of allergic disease. The purpose of this manuscript is to review the latest studies addressing the effect of SLIT on the development of new sensitizations in not sensitized or already sensitized patients and progression of the allergy march.
目的综述
特应性皮炎在婴儿期、变应性鼻炎和哮喘在儿童、青少年和成人期的进展，定义了过敏进程。变应原免疫治疗是唯一改变变态反应性疾病潜在免疫机制的病因治疗方法。舌下给药途径比皮下给药途径在儿科更易接受。
最近的发现
多项研究表明舌下免疫治疗（SLIT）治疗呼吸道变应性疾病的疗效和安全性，但关于其对变态反应性疾病的一级和二级预防作用的数据很少。本文的目的是综述最新的研究，探讨 SLIT 对未致敏或已致敏患者新致敏的发展以及过敏进程的影响。
Zotero 插件